Perrigo (PRGO)
Market Price (7/16/2026): $10.18 | Market Cap: $1.4 BilSector: Health Care | Industry: Pharmaceuticals
Perrigo (PRGO)
Market Price (7/16/2026): $10.18Market Cap: $1.4 BilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -26% Attractive yieldDividend Yield is 2.8%, FCF Yield is 7.7% Low stock price volatilityVol 12M is 48% Megatrend and thematic driversMegatrends include Health & Wellness Trends, and E-commerce & DTC Adoption. Themes include Nutritional Supplements, Organic & Natural Products, Show more. | Weak multi-year price returns2Y Excs Rtn is -92%, 3Y Excs Rtn is -136% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 18% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 233% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.6%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -2.8%, Rev Chg QQuarterly Revenue Change % is -7.2% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -130% Key risksPRGO key risks include [1] significant operational and legal challenges within its infant formula segment, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -26% |
| Attractive yieldDividend Yield is 2.8%, FCF Yield is 7.7% |
| Low stock price volatilityVol 12M is 48% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, and E-commerce & DTC Adoption. Themes include Nutritional Supplements, Organic & Natural Products, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -92%, 3Y Excs Rtn is -136% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 18% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 233% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.6%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -2.8%, Rev Chg QQuarterly Revenue Change % is -7.2% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -130% |
| Key risksPRGO key risks include [1] significant operational and legal challenges within its infant formula segment, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/9/2026
Perrigo (PRGO) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Mixed Fiscal First Quarter 2026 Financial Results with Reaffirmed Full-Year Guidance: Perrigo reported mixed results for fiscal Q1 2026 (ended March 31, 2026) on May 6, 2026, which contributed to a holding pattern for the stock. While adjusted earnings per share of $0.43 beat analyst estimates by $0.04, quarterly revenue declined 7.2% year-over-year to $841.80 million, falling below the consensus estimate of $1.04 billion. Despite the revenue miss and a non-cash goodwill impairment charge of $331 million, the company reaffirmed its full-year 2026 guidance, projecting results to be weighted to the second half, with approximately 65% to 70% of CORE adjusted earnings per share expected in that period. This combination of near-term weakness and reiterated future expectations likely kept the stock range-bound.
2. Strategic Portfolio Optimization and Debt Reduction Efforts: The company's ongoing strategic initiatives, including portfolio optimization, provided some underlying support for the stock. In April 2026, Perrigo completed the divestiture of its Dermacosmetics business, generating approximately €306 million in upfront proceeds, which are designated for debt reduction. This action aligns with the company's "Three-S plan" (stabilize, streamline, and strengthen) aimed at creating a more focused and financially sound business, which likely tempered steeper declines despite other negative news.
Show more
Perrigo (PRGO) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Mixed Fiscal First Quarter 2026 Financial Results with Reaffirmed Full-Year Guidance: Perrigo reported mixed results for fiscal Q1 2026 (ended March 31, 2026) on May 6, 2026, which contributed to a holding pattern for the stock. While adjusted earnings per share of $0.43 beat analyst estimates by $0.04, quarterly revenue declined 7.2% year-over-year to $841.80 million, falling below the consensus estimate of $1.04 billion. Despite the revenue miss and a non-cash goodwill impairment charge of $331 million, the company reaffirmed its full-year 2026 guidance, projecting results to be weighted to the second half, with approximately 65% to 70% of CORE adjusted earnings per share expected in that period. This combination of near-term weakness and reiterated future expectations likely kept the stock range-bound.
2. Strategic Portfolio Optimization and Debt Reduction Efforts: The company's ongoing strategic initiatives, including portfolio optimization, provided some underlying support for the stock. In April 2026, Perrigo completed the divestiture of its Dermacosmetics business, generating approximately €306 million in upfront proceeds, which are designated for debt reduction. This action aligns with the company's "Three-S plan" (stabilize, streamline, and strengthen) aimed at creating a more focused and financially sound business, which likely tempered steeper declines despite other negative news.
Show more
Updated on 7/9/2026
Perrigo (PRGO) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Mixed Fiscal First Quarter 2026 Financial Results with Reaffirmed Full-Year Guidance: Perrigo reported mixed results for fiscal Q1 2026 (ended March 31, 2026) on May 6, 2026, which contributed to a holding pattern for the stock. While adjusted earnings per share of $0.43 beat analyst estimates by $0.04, quarterly revenue declined 7.2% year-over-year to $841.80 million, falling below the consensus estimate of $1.04 billion. Despite the revenue miss and a non-cash goodwill impairment charge of $331 million, the company reaffirmed its full-year 2026 guidance, projecting results to be weighted to the second half, with approximately 65% to 70% of CORE adjusted earnings per share expected in that period. This combination of near-term weakness and reiterated future expectations likely kept the stock range-bound.
2. Strategic Portfolio Optimization and Debt Reduction Efforts: The company's ongoing strategic initiatives, including portfolio optimization, provided some underlying support for the stock. In April 2026, Perrigo completed the divestiture of its Dermacosmetics business, generating approximately €306 million in upfront proceeds, which are designated for debt reduction. This action aligns with the company's "Three-S plan" (stabilize, streamline, and strengthen) aimed at creating a more focused and financially sound business, which likely tempered steeper declines despite other negative news.
3. Leadership Transition Amidst Persistent Operational Headwinds: A significant leadership change occurred on June 8, 2026, when President and CEO Patrick Lockwood-Taylor resigned, leading to the appointment of Albert A. Manzone as Interim President and CEO. While the company stated this was due to personal conduct unrelated to its business or financials, this transition introduced an element of uncertainty. This occurred against a backdrop of ongoing operational challenges, including a 160 basis point decrease in core adjusted gross margin to 39.2% in fiscal Q1 2026 and an anticipated unfavorable all-in earnings per share impact of approximately $0.60 for fiscal year 2026 due to prior-year manufacturing volume headwinds, with about $0.26 of that impact realized in fiscal Q1 2026. These factors collectively contributed to investor caution, preventing significant upward movement.
Show less
Perrigo (PRGO) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Mixed Fiscal First Quarter 2026 Financial Results with Reaffirmed Full-Year Guidance: Perrigo reported mixed results for fiscal Q1 2026 (ended March 31, 2026) on May 6, 2026, which contributed to a holding pattern for the stock. While adjusted earnings per share of $0.43 beat analyst estimates by $0.04, quarterly revenue declined 7.2% year-over-year to $841.80 million, falling below the consensus estimate of $1.04 billion. Despite the revenue miss and a non-cash goodwill impairment charge of $331 million, the company reaffirmed its full-year 2026 guidance, projecting results to be weighted to the second half, with approximately 65% to 70% of CORE adjusted earnings per share expected in that period. This combination of near-term weakness and reiterated future expectations likely kept the stock range-bound.
2. Strategic Portfolio Optimization and Debt Reduction Efforts: The company's ongoing strategic initiatives, including portfolio optimization, provided some underlying support for the stock. In April 2026, Perrigo completed the divestiture of its Dermacosmetics business, generating approximately €306 million in upfront proceeds, which are designated for debt reduction. This action aligns with the company's "Three-S plan" (stabilize, streamline, and strengthen) aimed at creating a more focused and financially sound business, which likely tempered steeper declines despite other negative news.
3. Leadership Transition Amidst Persistent Operational Headwinds: A significant leadership change occurred on June 8, 2026, when President and CEO Patrick Lockwood-Taylor resigned, leading to the appointment of Albert A. Manzone as Interim President and CEO. While the company stated this was due to personal conduct unrelated to its business or financials, this transition introduced an element of uncertainty. This occurred against a backdrop of ongoing operational challenges, including a 160 basis point decrease in core adjusted gross margin to 39.2% in fiscal Q1 2026 and an anticipated unfavorable all-in earnings per share impact of approximately $0.60 for fiscal year 2026 due to prior-year manufacturing volume headwinds, with about $0.26 of that impact realized in fiscal Q1 2026. These factors collectively contributed to investor caution, preventing significant upward movement.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -3.0% change in PRGO stock from 3/31/2026 to 7/15/2026 was primarily driven by a -1.8% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 7152026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.47 | 10.15 | -3.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4,253 | 4,178 | -1.8% |
| P/S Multiple | 0.3 | 0.3 | -1.8% |
| Shares Outstanding (Mil) | 139 | 139 | 0.5% |
| Cumulative Contribution | -3.0% |
Market Drivers
3/31/2026 to 7/15/2026| Return | Correlation | |
|---|---|---|
| PRGO | -3.0% | |
| Market (SPY) | 16.1% | 24.7% |
| Sector (XLV) | 8.0% | 39.2% |
Fundamental Drivers
The -23.5% change in PRGO stock from 12/31/2025 to 7/15/2026 was primarily driven by a -21.5% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 7152026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.27 | 10.15 | -23.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4,282 | 4,178 | -2.4% |
| P/S Multiple | 0.4 | 0.3 | -21.5% |
| Shares Outstanding (Mil) | 138 | 139 | -0.1% |
| Cumulative Contribution | -23.5% |
Market Drivers
12/31/2025 to 7/15/2026| Return | Correlation | |
|---|---|---|
| PRGO | -23.5% | |
| Market (SPY) | 11.0% | 39.8% |
| Sector (XLV) | 2.7% | 39.0% |
Fundamental Drivers
The -58.8% change in PRGO stock from 6/30/2025 to 7/15/2026 was primarily driven by a -56.9% change in the company's P/S Multiple.| (LTM values as of) | 6302025 | 7152026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.62 | 10.15 | -58.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4,335 | 4,178 | -3.6% |
| P/S Multiple | 0.8 | 0.3 | -56.9% |
| Shares Outstanding (Mil) | 138 | 139 | -0.7% |
| Cumulative Contribution | -58.8% |
Market Drivers
6/30/2025 to 7/15/2026| Return | Correlation | |
|---|---|---|
| PRGO | -58.8% | |
| Market (SPY) | 23.2% | 28.8% |
| Sector (XLV) | 19.0% | 33.2% |
Fundamental Drivers
The -65.0% change in PRGO stock from 6/30/2023 to 7/15/2026 was primarily driven by a -60.7% change in the company's P/S Multiple.| (LTM values as of) | 6302023 | 7152026 | Change |
|---|---|---|---|
| Stock Price ($) | 28.97 | 10.15 | -65.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4,559 | 4,178 | -8.3% |
| P/S Multiple | 0.9 | 0.3 | -60.7% |
| Shares Outstanding (Mil) | 135 | 139 | -2.7% |
| Cumulative Contribution | -65.0% |
Market Drivers
6/30/2023 to 7/15/2026| Return | Correlation | |
|---|---|---|
| PRGO | -65.0% | |
| Market (SPY) | 76.3% | 27.7% |
| Sector (XLV) | 24.9% | 35.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PRGO Return | -11% | -10% | -2% | -17% | -43% | -25% | -72% |
| Peers Return | 22% | -9% | -0% | 16% | -13% | 8% | 20% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| PRGO Win Rate | 50% | 50% | 58% | 42% | 25% | 29% | |
| Peers Win Rate | 54% | 46% | 49% | 60% | 35% | 54% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| PRGO Max Drawdown | -27% | -26% | -32% | -27% | -57% | -38% | |
| Peers Max Drawdown | -18% | -30% | -17% | -16% | -33% | -19% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: KVUE, PG, VTRS, CHD, PBH. See PRGO Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/15/2026 (YTD)
How Low Can It Go
| Event | PRGO | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -10.7% | -6.7% |
| % Gain to Breakeven | 12.0% | 7.1% |
| Time to Breakeven | 51 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -17.4% | -24.5% |
| % Gain to Breakeven | 21.1% | 32.4% |
| Time to Breakeven | 16 days | 427 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -17.6% | -17.9% |
| % Gain to Breakeven | 21.4% | 21.8% |
| Time to Breakeven | 16 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -47.3% | -53.4% |
| % Gain to Breakeven | 89.9% | 114.4% |
| Time to Breakeven | 220 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -10.2% | -8.6% |
| % Gain to Breakeven | 11.3% | 9.5% |
| Time to Breakeven | 11 days | 47 days |
In The Past
Perrigo's stock fell -2.7% during the 2025 US Tariff Shock. Such a loss loss requires a 2.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PRGO | S&P 500 |
|---|---|---|
| 2008-2009 Global Financial Crisis | ||
| % Loss | -47.3% | -53.4% |
| % Gain to Breakeven | 89.9% | 114.4% |
| Time to Breakeven | 220 days | 1085 days |
In The Past
Perrigo's stock fell -2.7% during the 2025 US Tariff Shock. Such a loss loss requires a 2.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Perrigo (PRGO)
Perrigo Company plc (PRGO) is a global provider of over-the-counter (OTC) health and wellness solutions, specializing in products that empower consumers to self-manage their health. The company focuses on developing, manufacturing, and marketing a wide array of self-care products designed to prevent or treat common conditions without a prescription.
Perrigo operates through two primary segments. Its Consumer Self-Care Americas segment concentrates on store brand and branded self-care products across categories such as upper respiratory, pain relief, sleep aids, digestive health, nutrition, vitamins, and oral/skincare. Key brands in this segment include Prevacid 24HR, Good Sense, Burt's Bees, Plackers, and Rembrandt. This segment primarily serves consumers in the United States, Mexico, Canada, and South America, distributing products through various retail channels.
The Consumer Self-Care International segment extends Perrigo's reach, developing and distributing consumer self-care brands across approximately 23 countries, predominantly in Europe. These products are sold through pharmacies, wholesalers, and drug/grocery retailers. Additionally, Perrigo offers contract manufacturing services, leveraging its expertise to produce goods for other companies. This dual geographic and service approach positions Perrigo as a significant player in the global consumer healthcare market.
AI Analysis | Feedback
Here are 1-3 brief analogies for Perrigo (PRGO):
- Perrigo is like Viatris (the company behind generic prescription drugs) but for over-the-counter medications and wellness products.
- Perrigo is like Johnson & Johnson's consumer health division, but primarily focused on manufacturing 'store brand' versions of those products for other retailers.
AI Analysis | Feedback
- Prevacid 24HR: An over-the-counter medication for acid reduction.
- Good Sense: A brand offering a wide range of store-brand self-care products across various health categories.
- Zephrex D: Products focused on upper respiratory relief.
- ScarAway: Skincare products designed for scar treatment.
- Plackers: Oral self-care products, typically dental flossers.
- Rembrandt: Oral self-care products, often associated with teeth whitening.
- Steripod: Oral self-care products, such as toothbrush protectors.
- Firefly: Oral self-care products, often geared towards children's dental hygiene.
- REACH: Oral self-care products, including toothbrushes and floss.
- Dr. Fresh: Oral self-care products, such as toothbrushes and other dental hygiene items.
- Burt's Bees: A brand encompassing skincare and personal hygiene products.
- Contract Manufacturing Services: Manufacturing services provided to other companies for their products.
AI Analysis | Feedback
Perrigo (PRGO) primarily sells its products and services to other companies, specifically to a network of retailers, wholesalers, and healthcare providers who then sell to individual consumers. Given Perrigo's focus on store brand products and distribution through various channels, its major customers are likely large retail chains, pharmacies, and wholesalers.
Based on the company description, some of Perrigo's major customer companies would include:
- Large drug store chains such as:
- CVS Health Corp (CVS)
- Walgreens Boots Alliance, Inc. (WBA)
- Major mass merchandise and grocery retailers that sell over-the-counter (OTC) health and wellness products, including store brands:
- Walmart Inc. (WMT)
- Target Corporation (TGT)
- The Kroger Co. (KR)
- Pharmaceutical wholesalers and distributors.
- Other companies for whom Perrigo provides contract manufacturing services.
AI Analysis | Feedback
null
AI Analysis | Feedback
Patrick Lockwood-Taylor, President & Chief Executive Officer
Patrick Lockwood-Taylor was appointed President and Chief Executive Officer of Perrigo in June 2023. Prior to joining Perrigo, he served as President of Bayer USA and Regional President of Consumer Health North America for Bayer AG. Before his time at Bayer, he was the President and CEO of The Oneida Group Inc., a private company, from 2016 to 2018, where he led a significant transformation. He spent over 20 years at Procter & Gamble in various global leadership roles, including operations management, sales, marketing, country management, and general management across four continents. He also held the position of Vice President of Personal Health Care North America and Global Digestive Wellness at Procter & Gamble.
Eduardo Bezerra, Executive Vice President and Chief Financial Officer
Eduardo Bezerra was appointed Executive Vice President and Chief Financial Officer of Perrigo, effective May 16, 2022. Before joining Perrigo, Mr. Bezerra served as Senior Vice President and Chief Financial Officer at Fresh Del Monte Produce, Inc. (FDP).
Abbie Lennox, Executive Vice President and Chief Scientific Officer
Abbie Lennox was appointed Executive Vice President and Chief Scientific Officer in January 2025. She previously led teams at Bayer Consumer Health, bringing extensive experience in regulatory excellence, product life cycle management, and product innovation.
Matt Winterman, Executive Vice President, Product Supply, Operations Strategy & Transformation Officer
Matt Winterman was appointed Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025, succeeding Ron Janish. He brings over 20 years of global supply chain and strategy leadership experience. Most recently, he served as Senior Vice President of Global Supply Chain and Strategy at AstraZeneca, where he oversaw a $54 billion supply chain. His prior roles included Global Head of end-to-end Supply Chain at Roche Holding AG and various positions at GSK plc focused on technical operations strategy and supply chain performance.
Roberto Khoury, Executive Vice President and Chief Commercial Officer
Roberto Khoury serves as the Executive Vice President and Chief Commercial Officer at Perrigo.
AI Analysis | Feedback
The key risks to Perrigo's business include challenges within its infant formula segment and related litigation, intense competition in the consumer self-care market, and ongoing regulatory scrutiny and compliance risks.
- Challenges in the Infant Formula Business and Related Litigation: Perrigo has faced significant operational problems, unexpected expenses, and disappointing sales within its infant formula business, which it acquired from Nestlé. This has led to a class-action lawsuit alleging securities fraud due to the company's failure to disclose underlying issues and underinvestment in the acquired facilities. Analysts have expressed skepticism about the company's ability to navigate this crisis, and Perrigo has acknowledged that the external environment has made the infant formula business "less strategic" for its consumer health OTC operations. The infant formula market is also highly volatile and subject to intense regulatory scrutiny.
- Intense Competition in the Consumer Self-Care Market: Perrigo operates in a highly competitive global market for over-the-counter (OTC) health and wellness products. It faces significant rivalry from large pharmaceutical firms with substantial research and development budgets, well-established brands, and extensive distribution networks. Additionally, competition from private-label manufacturers, who focus on price and efficiency for generic OTC drugs, presents a continuous challenge across Perrigo's diverse product categories and geographic regions.
- Regulatory Scrutiny and Compliance Risks: As a provider of health and wellness solutions, Perrigo operates within a highly regulated environment, subject to stringent requirements from agencies such as the U.S. Food and Drug Administration (FDA). The inability to meet current or future regulatory demands can materially affect the company's business and operating results, leading to costly penalties, product recalls, and delays in product launches. Past instances of manufacturing violations have been cited, highlighting the continuous need for adept navigation of regulatory landscapes to ensure compliance.
AI Analysis | Feedback
The increasing market share captured by direct-to-consumer (DTC) health, wellness, and personal care brands. These brands often bypass traditional retail channels (pharmacies, wholesalers, drug and grocery stores) by selling directly to consumers online, frequently leveraging subscription models and targeted digital marketing. This shift in distribution and consumer purchasing behavior directly challenges Perrigo's established business model, which heavily relies on traditional retail shelf space and distribution networks for its store brand and proprietary self-care products.
AI Analysis | Feedback
Perrigo Company plc (PRGO) operates in several significant addressable markets for its over-the-counter (OTC) health and wellness products across the Americas and Europe.
Overall OTC Market
- The global over-the-counter (OTC) drugs market was estimated at approximately USD 135.25 billion in 2025 and is projected to reach about USD 256.87 billion by 2035.
- In North America, the OTC consumer health products market was valued at USD 82.70 billion in 2025. The North America OTC drugs market was valued at USD 39.77 billion in 2025.
- For Europe, the OTC drugs market was estimated at USD 55.5 billion in 2025 and is expected to reach USD 90.8 billion by 2034. Other estimates for the Europe OTC drugs market include USD 36.6 billion in 2025, growing to USD 46.42 billion by 2031, and USD 65.11 billion in 2024, projected to reach USD 131.02 billion by 2033. The Europe OTC Consumer Health Products Market size was USD 64.82 billion in 2025.
Main Product Categories
Upper Respiratory (Cold and Cough Remedies)
- The cold and cough remedies segment in Europe dominated its market, valued at USD 12.9 billion in 2024.
- In the U.S., OTC cough, cold, and flu remedies held a 27.65% share of the overall U.S. OTC drugs market in 2025. With the U.S. OTC drugs market valued at USD 44.68 billion in 2025, this segment represents approximately USD 12.35 billion.
- The global upper respiratory tract infection treatment market size was USD 15.67 billion in 2024 and is projected to reach USD 30.37 billion by 2035.
Pain and Sleep-aids
- Pain Relief (Analgesics): The global over-the-counter (OTC) analgesics market is expected to grow from USD 30.16 billion in 2025 to USD 37.93 billion by 2031, with another estimate of USD 31.89 billion in 2025 growing to USD 45.77 billion by 2035. The global OTC pain medication market was estimated at USD 27.12 billion in 2024 and is expected to surpass USD 35.50 billion by 2031. The U.S. OTC pain management market is estimated to reach USD 9 billion by 2029.
- Sleep-aids: The global sleep aids market was valued at USD 12.9 billion in 2024 and is poised to grow to USD 22.36 billion by 2033. Another source estimates the global sleep aids market at USD 67.31 billion in 2025, growing to USD 100.59 billion by 2032. The U.S. sleep aids market size was valued at USD 29.65 billion in 2022 and is projected to reach USD 54.73 billion by 2032. The global OTC sleep aids medication market is expected to reach US$25.53 billion in 2030 from US$20.11 billion in 2025.
Digestive Health
- The global digestive health supplements market is estimated at USD 12.22 billion in 2025 and is expected to reach USD 25.83 billion by 2035.
- In the U.S., the digestive health products market was estimated at USD 13.53 billion in 2023 and is expected to reach USD 23.53 billion by 2030. The U.S. digestive health supplements market was estimated at USD 4.64 billion in 2025 and is expected to reach USD 9.81 billion by 2035.
Nutrition, Vitamins, Minerals, and Supplements (VMS)
- The global vitamins and supplements market size was USD 164.4 billion in 2025 and is anticipated to grow to USD 284.26 billion by 2034.
- The U.S. dietary supplement market reached USD 69.3 billion in 2024, with vitamins representing 27.5% of this market. The demand for vitamin and mineral supplements in the USA is projected to grow from USD 21.3 billion in 2025 to USD 35.1 billion by 2035. The U.S. vitamin supplements market size was estimated at USD 15.06 billion in 2024 and is projected to reach USD 21.37 billion by 2033.
Skincare and Personal Hygiene
- The global skincare market is expected to exceed USD 222 billion by 2030.
- The U.S. skincare market size was around USD 25.04 billion in 2024 and is predicted to grow to around USD 36.56 billion by 2034. Other estimates for the U.S. skincare market include USD 30.01 billion in 2024, projected to reach USD 39.81 billion by 2030.
- Dermatological products represent approximately 34.7% of the global OTC consumer healthcare market, which was valued at US$207.8 billion in 2025, implying a market size of approximately USD 72.19 billion for global dermatological products.
Oral Self-Care
- The global oral care market was valued at USD 34.76 billion in 2025 and is projected to grow to USD 51.25 billion by 2034. Another estimate places the global oral care market at USD 43.29 billion in 2025, increasing to USD 83.12 billion by 2035.
- The U.S. oral care market was valued at USD 5.75 billion in 2024 and is projected to reach USD 9.66 billion by 2034. Other estimates for the U.S. oral care market include USD 10.03 billion in 2024, projected to reach USD 13.02 billion by 2030, and USD 11.1 billion in 2025, projected to reach USD 20.6 billion by 2034.
Store Brand/Private Label OTC Products
- Private-label OTC medicines accounted for over 37% of retail pharmacy shelf space in the U.S. in 2023. In 2023, private label sales in the U.S. OTC pharmaceuticals market rose to 31%. These products are often priced 20%–40% lower than branded equivalents.
AI Analysis | Feedback
Perrigo (PRGO) is focused on several key initiatives to drive future revenue growth over the next two to three years. These strategies aim to leverage its core strengths in consumer self-care and expand its market presence.
The expected drivers of future revenue growth for Perrigo include:
* New Product Launches and Innovation: Perrigo is emphasizing a robust pipeline of new products, particularly in high-growth categories such as Women's Health and Skin Care. A significant driver is the 2024 U.S. launch of Opill, the first FDA-approved over-the-counter (OTC) daily oral contraceptive, which is expected to redefine the company's role as a self-care category creator. The company's innovation capabilities have reportedly tripled in value compared to the previous year.
* Strategic Portfolio Optimization: Perrigo is strategically refining its product portfolio to focus on higher-margin and core self-care categories. This involves targeted "tuck-in" acquisitions in areas like women's health, dermatology, and digestive wellness, along with selective Rx-to-OTC switches. Concurrently, the company is divesting non-core assets, such as its Dermacosmetics and Rare Diseases businesses, to streamline operations and enhance its core business segments.
* Global Expansion of Key Brands: The company plans to accelerate profitable growth through the global expansion of its key brands. This includes extending the geographic reach and line extensions of brands acquired through HRA Pharma, such as Compeed and Mederma across European markets, and providing targeted support for ellaOne. Perrigo anticipates outperforming the market in the latter half of 2026 through continued innovation and geographic expansion.
* Expansion of the E-commerce Business: Perrigo is making further investments in its high-growth e-commerce business, recognizing its potential to contribute to organic net sales growth.
* Growth in the Store Brand OTC Market and Enhanced Retailer Partnerships: Perrigo is actively pursuing new business awards within the store brand OTC market and strengthening its partnerships with retailers. The company has reported significant market share gains in U.S. store brands, with efforts to convert consumer cost-consciousness into steady demand.
AI Analysis | Feedback
Outbound Investments
- Perrigo acquired HRA Pharma in September 2021 for $2.13 billion, a strategic move to bolster its consumer self-care portfolio, particularly in Europe.
- The company divested its Generic Rx Pharmaceuticals business to Altaris Capital Partners for $1.55 billion in March 2021, marking a significant step in its transformation into a pure-play global consumer self-care company.
- Perrigo agreed to sell its Dermacosmetics-branded business for up to €327 million (approximately $374 million) in July 2025, with the transaction expected to close in the second quarter of 2026, and proceeds intended for debt reduction.
Capital Expenditures
- Year-to-date capital expenditures for the full year 2025 were reported at $93 million.
- In the first nine months of calendar year 2025, Perrigo allocated $67 million for investments, following approximately $81 million in the same period of 2024.
- Perrigo has made strategic investments in key brand initiatives, such as EllaOne and Nasonex, and is focusing on leveraging its U.S. manufacturing capabilities for contract manufacturing, particularly in infant formula and oral care.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 33.53 |
| Mkt Cap | 21.1 |
| Rev LTM | 10,384 |
| Op Inc LTM | 691 |
| FCF LTM | 1,361 |
| FCF 3Y Avg | 1,355 |
| CFO LTM | 1,687 |
| CFO 3Y Avg | 1,687 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 0.8% |
| Rev Chg 3Y Avg | -0.5% |
| Rev Chg Q | 2.3% |
| QoQ Delta Rev Chg LTM | 0.6% |
| Op Inc Chg LTM | -9.2% |
| Op Inc Chg 3Y Avg | 2.5% |
| Op Mgn LTM | 18.2% |
| Op Mgn 3Y Avg | 17.8% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 17.2% |
| CFO/Rev 3Y Avg | 16.9% |
| FCF/Rev LTM | 14.6% |
| FCF/Rev 3Y Avg | 13.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 21.1 |
| P/S | 2.2 |
| P/Op Inc | 14.7 |
| P/EBIT | 10.6 |
| P/E | 16.4 |
| P/CFO | 12.4 |
| Total Yield | 4.6% |
| Dividend Yield | 2.0% |
| FCF Yield 3Y Avg | 5.3% |
| D/E | 0.4 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.5% |
| 3M Rtn | 3.5% |
| 6M Rtn | 5.5% |
| 12M Rtn | -4.4% |
| 3Y Rtn | -7.1% |
| 1M Excs Rtn | -1.5% |
| 3M Excs Rtn | -6.0% |
| 6M Excs Rtn | 0.1% |
| 12M Excs Rtn | -26.4% |
| 3Y Excs Rtn | -78.6% |
Comparison Analyses
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA215712 | NASONEX 24HR ALLERGY | mometasone furoate | spray, metered | 3172022 | -2.5% | 4.5% | -7.1% | -16.0% | -67.9% |
| ANDA213650 | SUMATRIPTAN | sumatriptan | spray | 9212020 | -2.0% | -6.4% | -4.9% | -11.6% | -72.1% |
| ANDA208478 | ATORVASTATIN CALCIUM | atorvastatin calcium | tablet | 6232020 | -15.1% | -19.7% | -14.7% | -23.3% | -76.7% |
| ANDA205791 | SILDENAFIL CITRATE | sildenafil citrate | tablet | 4232020 | 11.0% | -10.1% | -16.4% | -30.9% | -74.7% |
| ANDA210033 | LORATADINE | loratadine | tablet, chewable | 6122019 | 27.8% | 25.0% | 19.9% | 13.9% | -69.9% |
| ANDA211253 | DICLOFENAC SODIUM | diclofenac sodium | gel | 5162019 | -8.1% | -2.8% | 7.5% | -4.7% | -73.7% |
| ANDA208499 | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | diphenhydramine hydrochloride | tablet | 5102019 | -9.4% | -2.9% | 3.0% | -14.4% | -74.8% |
| ANDA211983 | LEVOCETIRIZINE DIHYDROCHLORIDE | levocetirizine dihydrochloride | tablet | 3282019 | -1.2% | 14.9% | -1.1% | -8.1% | -72.3% |
| ANDA209837 | LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE | loperamide hydrochloride | tablet | 9052018 | -18.2% | -38.2% | -36.5% | -31.8% | -82.8% |
| ANDA207602 | GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE | dextromethorphan hydrobromide | tablet, extended release | 3052018 | -10.7% | -7.1% | -39.2% | -31.5% | -84.0% |
| ... | |||||||||
| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA215712 | NASONEX 24HR ALLERGY | mometasone furoate | spray, metered | 3172022 | -2.5% | 4.5% | -7.1% | -16.0% | -67.9% |
| ANDA213650 | SUMATRIPTAN | sumatriptan | spray | 9212020 | -2.0% | -6.4% | -4.9% | -11.6% | -72.1% |
| ANDA208478 | ATORVASTATIN CALCIUM | atorvastatin calcium | tablet | 6232020 | -15.1% | -19.7% | -14.7% | -23.3% | -76.7% |
| ANDA205791 | SILDENAFIL CITRATE | sildenafil citrate | tablet | 4232020 | 11.0% | -10.1% | -16.4% | -30.9% | -74.7% |
| ANDA210033 | LORATADINE | loratadine | tablet, chewable | 6122019 | 27.8% | 25.0% | 19.9% | 13.9% | -69.9% |
| ANDA211253 | DICLOFENAC SODIUM | diclofenac sodium | gel | 5162019 | -8.1% | -2.8% | 7.5% | -4.7% | -73.7% |
| ANDA208499 | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | diphenhydramine hydrochloride | tablet | 5102019 | -9.4% | -2.9% | 3.0% | -14.4% | -74.8% |
| ANDA211983 | LEVOCETIRIZINE DIHYDROCHLORIDE | levocetirizine dihydrochloride | tablet | 3282019 | -1.2% | 14.9% | -1.1% | -8.1% | -72.3% |
| ANDA209837 | LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE | loperamide hydrochloride | tablet | 9052018 | -18.2% | -38.2% | -36.5% | -31.8% | -82.8% |
| ANDA207602 | GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE | dextromethorphan hydrobromide | tablet, extended release | 3052018 | -10.7% | -7.1% | -39.2% | -31.5% | -84.0% |
| ANDA207193 | ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium | capsule, delayed release | 8182017 | 11.4% | 16.3% | -4.8% | -38.8% | -82.7% |
| ANDA206393 | NICOTINE POLACRILEX | nicotine polacrilex | gum, chewing | 12152016 | -14.0% | -11.5% | 5.6% | -29.7% | -83.7% |
| ANDA206394 | NICOTINE POLACRILEX | nicotine polacrilex | gum, chewing | 12152016 | -14.0% | -11.5% | 5.6% | -29.7% | -83.7% |
| ANDA204782 | FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE | calcium carbonate | tablet, chewable | 8292016 | -0.8% | -4.7% | -12.1% | -14.6% | -84.9% |
| ANDA201361 | OMEPRAZOLE AND SODIUM BICARBONATE | omeprazole | capsule | 7152016 | -8.6% | -17.6% | -21.4% | -18.5% | -85.8% |
| ANDA205490 | CETIRIZINE HYDROCHLORIDE ALLERGY | cetirizine hydrochloride | tablet, orally disintegrating | 9022015 | -18.5% | -30.6% | -49.5% | -56.0% | -92.6% |
| ANDA206581 | IBUPROFEN SODIUM | ibuprofen sodium | tablet | 8032015 | -17.2% | -25.2% | -52.2% | -62.1% | -93.0% |
| ANDA204152 | OMEPRAZOLE MAGNESIUM | omeprazole magnesium | tablet, delayed release | 7302015 | -13.3% | -25.1% | -52.1% | -60.6% | -92.9% |
| ANDA202334 | LEVONORGESTREL | levonorgestrel | tablet | 8202014 | 6.4% | 0.9% | 29.3% | -38.1% | -90.9% |
| ANDA203200 | IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE | ibuprofen | tablet | 7032014 | -1.1% | 9.2% | 20.1% | -40.1% | -91.2% |
| ANDA204226 | CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY | cetirizine hydrochloride | solution | 9092013 | 25.5% | 34.3% | 16.5% | 44.5% | -89.0% |
| NDA203098 | TESTOSTERONE | testosterone | gel | 1312013 | 18.1% | 25.0% | 55.3% | 51.8% | -86.4% |
| ANDA202319 | LANSOPRAZOLE | lansoprazole | capsule, delayed rel pellets | 5182012 | 7.7% | 2.8% | 20.7% | 34.5% | -86.2% |
| ANDA078361 | DESLORATADINE | desloratadine | tablet | 12222011 | 2.8% | 13.7% | 2.3% | 52.0% | -86.4% |
| ANDA078912 | GUAIFENESIN | guaifenesin | tablet, extended release | 11232011 | 5.3% | 12.6% | 13.8% | 73.5% | -84.8% |
| ANDA091349 | NICOTINE POLACRILEX | nicotine polacrilex | gum, chewing | 7202011 | 4.0% | 8.1% | 24.5% | 40.8% | -85.2% |
| ANDA091354 | NICOTINE POLACRILEX | nicotine polacrilex | gum, chewing | 7202011 | 4.0% | 8.1% | 24.5% | 40.8% | -85.2% |
| ANDA091292 | LOPERAMIDE HYDROCHLORIDE | loperamide hydrochloride | solution | 5202011 | -0.3% | 7.1% | 16.5% | 40.6% | -84.0% |
| ANDA091429 | RANITIDINE HYDROCHLORIDE | ranitidine hydrochloride | tablet | 5112011 | -3.9% | 2.7% | 16.1% | 38.2% | -84.3% |
| ANDA091344 | MINOXIDIL | minoxidil | aerosol, foam | 4282011 | 0.7% | 0.2% | 17.8% | 32.2% | -84.8% |
| ANDA079114 | MICONAZOLE NITRATE | miconazole nitrate | cream, insert | 6022010 | 1.0% | 6.6% | 49.8% | 77.7% | -76.1% |
| ANDA091366 | MICONAZOLE NITRATE | miconazole nitrate | cream | 1152010 | 43.4% | 36.2% | 59.8% | 132.0% | -67.3% |
| ANDA078104 | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | spray, metered | 7302009 | 34.9% | 59.6% | 105.9% | 233.3% | -49.5% |
| ANDA090821 | NICOTINE POLACRILEX | nicotine polacrilex | troche/lozenge | 7102009 | 35.6% | 42.4% | 119.3% | 245.6% | -48.1% |
| NDA022327 | PREVACID 24 HR | lansoprazole | capsule, delayed rel pellets | 5182009 | -0.8% | 49.9% | 120.0% | 225.1% | -48.3% |
| ANDA079113 | IBUPROFEN AND DIPHENHYDRAMINE CITRATE | diphenhydramine citrate | tablet | 12222008 | -27.9% | -20.1% | 21.9% | 104.4% | -57.2% |
| ANDA078967 | NICOTINE POLACRILEX | nicotine polacrilex | gum, chewing | 4232008 | -7.8% | -23.0% | -37.2% | 55.1% | -64.8% |
| ANDA078968 | NICOTINE POLACRILEX | nicotine polacrilex | gum, chewing | 4232008 | -7.8% | -23.0% | -37.2% | 55.1% | -64.8% |
| ANDA090254 | CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF | cetirizine hydrochloride | solution | 4092008 | -12.5% | -12.0% | -37.9% | 51.6% | -64.6% |
| ANDA077355 | FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE | calcium carbonate | tablet, chewable | 2062008 | -2.2% | 6.9% | -29.8% | 34.4% | -59.1% |
| ANDA078336 | CETIRIZINE HYDROCHLORIDE HIVES | cetirizine hydrochloride | tablet | 12272007 | 5.6% | -8.5% | -11.5% | 11.0% | -61.3% |
| ANDA078546 | NICOTINE POLACRILEX | nicotine polacrilex | gum, chewing | 5242007 | 3.4% | 51.3% | 83.1% | 38.6% | -28.7% |
| ANDA078547 | NICOTINE POLACRILEX | nicotine polacrilex | gum, chewing | 5242007 | 3.4% | 51.3% | 83.1% | 38.6% | -28.7% |
| ANDA078325 | NICOTINE POLACRILEX | nicotine polacrilex | gum, chewing | 10302006 | -3.6% | 5.8% | 31.0% | 76.5% | -21.7% |
| ANDA078326 | NICOTINE POLACRILEX | nicotine polacrilex | gum, chewing | 10302006 | -3.6% | 5.8% | 31.0% | 76.5% | -21.7% |
| ANDA077351 | FAMOTIDINE | famotidine | tablet | 9252006 | 4.3% | 4.4% | 32.1% | 132.1% | -15.0% |
| ANDA077007 | NICOTINE POLACRILEX | nicotine polacrilex | troche/lozenge | 1312006 | 0.4% | 1.3% | 11.9% | 101.4% | -8.7% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Consumer Self-Care Americas (CSCA) | 2,585 | 2,694 | 2,962 | 2,926 | 2,693 |
| Consumer Self-Care International (CSCI) | 1,668 | 1,680 | 1,693 | 1,526 | 1,446 |
| Unallocated | 0 | 0 | 0 | ||
| Held for sale | 0 | ||||
| Total | 4,253 | 4,373 | 4,656 | 4,452 | 4,139 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Unallocated | -224 | -262 | -202 | -257 | 168 |
| Consumer Self-Care International (CSCI) | -229 | 105 | -35 | -30 | 36 |
| Consumer Self-Care Americas (CSCA) | -669 | 270 | 390 | 366 | 206 |
| Held for sale | 0 | ||||
| Total | -1,122 | 113 | 152 | 79 | 410 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Consumer Self-Care International (CSCI) | 5,044 | 4,960 | 5,856 | 5,883 | 4,426 |
| Consumer Self-Care Americas (CSCA) | 3,491 | 4,688 | 4,953 | 5,134 | 5,984 |
| Unallocated | 0 | 0 | |||
| Held for sale | 16 | ||||
| Total | 8,535 | 9,648 | 10,809 | 11,017 | 10,426 |
Price Behavior
Price Behavior
| Market Price | $10.15 | |
| Market Cap ($ Bil) | 1.4 | |
| First Trading Date | 12/17/1991 | |
| Distance from 52W High | -61.2% | |
| 50 Days | 200 Days | |
| DMA Price | $10.65 | $12.98 |
| DMA Trend | down | down |
| Distance from DMA | -4.7% | -21.8% |
| 3M | 1YR | |
| Volatility | 46.9% | 48.3% |
| Downside Capture | 128.30 | 150.16 |
| Upside Capture | 48.27 | 9.58 |
| Correlation (SPY) | 20.5% | 28.5% |
PRGO Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.10 | 0.60 | 1.30 | 1.38 | 1.12 | 0.73 |
| Up Beta | -1.25 | 0.50 | 2.31 | 2.17 | 2.20 | 0.92 |
| Down Beta | -0.71 | -0.14 | 0.19 | 0.92 | 0.90 | 0.65 |
| Up Capture | 42% | 39% | 87% | 82% | 8% | 10% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 9 | 18 | 31 | 59 | 112 | 348 |
| Down Capture | 101% | 135% | 126% | 149% | 129% | 97% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 11 | 22 | 31 | 65 | 139 | 397 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRGO | |
|---|---|---|---|---|
| PRGO | -60.0% | 48.2% | -1.72 | - |
| Sector ETF (XLV) | 18.8% | 15.8% | 0.90 | 33.0% |
| Equity (SPY) | 21.9% | 12.6% | 1.30 | 29.0% |
| Gold (GLD) | 21.0% | 27.9% | 0.67 | 10.4% |
| Commodities (DBC) | 29.1% | 18.9% | 1.22 | -16.5% |
| Real Estate (VNQ) | 12.6% | 13.9% | 0.61 | 32.0% |
| Bitcoin (BTCUSD) | -46.2% | 42.9% | -1.32 | 13.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRGO | |
|---|---|---|---|---|
| PRGO | -23.2% | 36.7% | -0.63 | - |
| Sector ETF (XLV) | 5.8% | 14.9% | 0.21 | 34.3% |
| Equity (SPY) | 13.2% | 17.1% | 0.59 | 29.6% |
| Gold (GLD) | 17.2% | 18.4% | 0.76 | 4.9% |
| Commodities (DBC) | 9.0% | 19.5% | 0.35 | 0.7% |
| Real Estate (VNQ) | 2.7% | 18.9% | 0.04 | 30.3% |
| Bitcoin (BTCUSD) | 13.8% | 53.5% | 0.44 | 14.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRGO | |
|---|---|---|---|---|
| PRGO | -17.4% | 37.4% | -0.39 | - |
| Sector ETF (XLV) | 10.0% | 16.6% | 0.49 | 40.5% |
| Equity (SPY) | 15.6% | 17.9% | 0.74 | 37.9% |
| Gold (GLD) | 11.1% | 16.1% | 0.56 | 4.2% |
| Commodities (DBC) | 6.7% | 18.0% | 0.29 | 9.4% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 33.2% |
| Bitcoin (BTCUSD) | 57.9% | 66.2% | 0.98 | 11.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/30/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | 5.3% | -4.5% | -5.9% |
| 2/26/2026 | -1.5% | -17.1% | -33.4% |
| 11/5/2025 | -25.2% | -29.2% | -32.0% |
| 8/6/2025 | -11.3% | -13.3% | -11.4% |
| 5/7/2025 | 7.0% | 6.2% | 6.4% |
| 2/27/2025 | 20.2% | 18.9% | 17.5% |
| 11/6/2024 | 7.7% | 4.0% | 13.2% |
| 8/2/2024 | -2.1% | -1.0% | 4.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 9 | 9 |
| # Negative | 11 | 13 | 13 |
| Median Positive | 5.3% | 5.9% | 7.9% |
| Median Negative | -11.0% | -9.4% | -9.5% |
| Max Positive | 20.2% | 19.3% | 24.5% |
| Max Negative | -25.2% | -29.2% | -33.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | 5.3% | -4.5% | -5.9% |
| 2/26/2026 | -1.5% | -17.1% | -33.4% |
| 11/5/2025 | -25.2% | -29.2% | -32.0% |
| 8/6/2025 | -11.3% | -13.3% | -11.4% |
| 5/7/2025 | 7.0% | 6.2% | 6.4% |
| 2/27/2025 | 20.2% | 18.9% | 17.5% |
| 11/6/2024 | 7.7% | 4.0% | 13.2% |
| 8/2/2024 | -2.1% | -1.0% | 4.3% |
| 5/7/2024 | -9.8% | -7.9% | -20.2% |
| 2/27/2024 | -15.1% | -18.5% | -3.3% |
| 11/7/2023 | 4.0% | -1.1% | 5.0% |
| 8/8/2023 | 8.5% | 5.9% | -5.9% |
| 5/9/2023 | -3.1% | -4.9% | -5.5% |
| 2/27/2023 | 3.7% | 1.7% | -4.1% |
| 11/8/2022 | -15.3% | -16.9% | -18.9% |
| 5/11/2022 | 2.9% | 19.3% | 24.5% |
| 3/1/2022 | 3.9% | 1.7% | 7.9% |
| 11/10/2021 | -11.0% | -9.4% | -22.2% |
| 8/11/2021 | -12.6% | -15.2% | -9.5% |
| 3/1/2021 | 4.7% | 1.7% | 4.6% |
| 11/4/2020 | 9.5% | 14.1% | 21.3% |
| 8/5/2020 | -5.7% | -3.9% | -5.2% |
| SUMMARY STATS | |||
| # Positive | 11 | 9 | 9 |
| # Negative | 11 | 13 | 13 |
| Median Positive | 5.3% | 5.9% | 7.9% |
| Median Negative | -11.0% | -9.4% | -9.5% |
| Max Positive | 20.2% | 19.3% | 24.5% |
| Max Negative | -25.2% | -29.2% | -33.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/01/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/11/2021 | 10-Q |
| 03/31/2021 | 05/12/2021 | 10-Q |
| 12/31/2020 | 03/01/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/05/2020 | 10-Q |
| 03/31/2020 | 05/05/2020 | 10-Q |
| 12/31/2019 | 02/27/2020 | 10-K |
| 09/30/2019 | 11/06/2019 | 10-Q |
| 06/30/2019 | 08/08/2019 | 10-Q |
Recent Forward Guidance
Updated 7/12/2026Latest: Q1 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net Sales Growth (All In) | -5.5% | -3.5% | -1.5% | 0.0% | Affirmed | Guidance: -3.5% for 2026 | |
| 2026 Adj. Gross Margin (All In) | 36.5% | 37.0% | 37.5% | ||||
| 2026 Adj. Operating Margin (All In) | 12.5% | 13.0% | 13.5% | ||||
| 2026 Adj. EPS (All In) | 2 | 2.15 | 2.3 | 0.0% | Affirmed | Guidance: 2.15 for 2026 | |
| 2026 Net Sales Growth (Core) | -3.0% | -1.0% | 1.0% | 0.0% | Affirmed | Guidance: -1.0% for 2026 | |
| 2026 Adj. Gross Margin (Core) | 39.0% | 39.5% | 40.0% | ||||
| 2026 Adj. Operating Margin (Core) | 15.0% | 15.5% | 16.0% | ||||
| 2026 Adj. EPS (Core) | 2.25 | 2.4 | 2.55 | 0.0% | Affirmed | Guidance: 2.4 for 2026 | |
| 2026 Net interest expense | 156.00 Mil | ||||||
| 2026 Adjusted effective tax rate | 20.0% | ||||||
| 2026 Adjusted weighted average shares outstanding | 140.50 Mil | ||||||
| 2026 Net leverage | 4 | ||||||
| 2026 Cash from operating activities as percentage of adjusted net income | 0.65 | ||||||
Prior: Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net Sales Growth | -5.5% | -3.5% | -1.5% | -0.8% | Lower New | Actual: -2.75% for 2025 | |
| 2026 Adjusted EPS | 2 | 2.15 | 2.3 | -21.8% | Lower New | Actual: 2.75 for 2025 | |
| 2026 CORE Net Sales Growth | -3.0% | -1.0% | 1.0% | ||||
| 2026 CORE Organic Net Sales Growth | -3.5% | -1.5% | 0.5% | ||||
| 2026 CORE Adjusted EPS | 2.25 | 2.4 | 2.55 | ||||
| 2027 Operational Enhancement Program Savings | 80.00 Mil | 90.00 Mil | 100.00 Mil | ||||
Q3 2025 Earnings Reported 11/5/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Net Sales Growth | -3.0% | -2.75% | -2.5% | -4.2% | Lowered | Guidance: 1.5% for 2025 | |
| 2025 Organic Net Sales Growth | -2.5% | -2.25% | -2.0% | -5.2% | Lowered | Guidance: 3.0% for 2025 | |
| 2025 Adjusted EPS | 2.7 | 2.75 | 2.8 | -8.3% | Lowered | Guidance: 3 for 2025 | |
| 2025 EPS Growth | 5.0% | 7.0% | 9.0% | ||||
| 2025 Adjusted Gross Margin | 39.0% | -1.0% | Lowered | Guidance: 40.0% for 2025 | |||
| 2025 Adjusted Operating Margin | 15.0% | 0.0% | Affirmed | Guidance: 15.0% for 2025 | |||
| 2025 Interest Expense | 155.00 Mil | ||||||
| 2025 Adjusted Effective Tax Rate | 18.5% | ||||||
| 2025 Adjusted Weighted Average Shares Outstanding | 138.50 Mil | ||||||
| 2025 Net Leverage | 3.8 | ||||||
Insider Activity
Updated 7/15/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Parker, Geoffrey M | IRA | Buy | 11132025 | 14.18 | 7,500 | 106,350 | 246,378 | Form | |
| 2 | Lennox, Abigail | EVP and CSO | Direct | Buy | 9102025 | 22.41 | 1,255 | 28,125 | 28,125 | Form |
| 3 | Atkinson, Charles | EVP, General Counsel & Sec. | Direct | Buy | 9082025 | 23.20 | 1,000 | 23,200 | 23,200 | Form |
| 4 | Willis, Robert | EVP & CHRO | Direct | Buy | 8222025 | 24.10 | 1,488 | 35,858 | 1,010,646 | Form |
| 5 | Parker, Geoffrey M | Direct | Buy | 8192025 | 22.97 | 4,375 | 100,497 | 764,629 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Parker, Geoffrey M | IRA | Buy | 11132025 | 14.18 | 7,500 | 106,350 | 246,378 | Form | |
| 2 | Lennox, Abigail | EVP and CSO | Direct | Buy | 9102025 | 22.41 | 1,255 | 28,125 | 28,125 | Form |
| 3 | Atkinson, Charles | EVP, General Counsel & Sec. | Direct | Buy | 9082025 | 23.20 | 1,000 | 23,200 | 23,200 | Form |
| 4 | Willis, Robert | EVP & CHRO | Direct | Buy | 8222025 | 24.10 | 1,488 | 35,858 | 1,010,646 | Form |
| 5 | Parker, Geoffrey M | Direct | Buy | 8192025 | 22.97 | 4,375 | 100,497 | 764,629 | Form | |
| 6 | Bezerra, Eduardo Guarita | EVP & Chief Financial Officer | Direct | Buy | 8192025 | 22.74 | 3,000 | 68,207 | 1,112,885 | Form |
| 7 | Lockwood-Taylor, Patrick | CEO | Direct | Buy | 8082025 | 22.37 | 4,460 | 99,766 | 1,919,540 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Pharmaceuticals Resources |
| Fierce Pharma |
| Pharm Exec |
| Endpoints News |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/15/2026